Fierce Pharma

MARCH 12, 2024

Despite Moderna’s efforts to prove its mRNA thesis beyond COVID-19 in 2023, the post-pandemic hangover took a toll on the company. | Despite Moderna’s efforts to prove its mRNA thesis beyond COVID-19 in 2023, the post-pandemic hangover took a heavy toll on the company. In turn, much of the company’s top brass—including CEO Stéphane Bancel—saw their total compensation fall for the year.

227

227

MedCity News

MARCH 12, 2024

At HIMSS, Google Cloud announced new AI features designed to assist providers, payers and any other healthcare organizations seeking to make better use of their clinical data.

Healthcare 141

Healthcare Healthcare 141

Fierce Pharma

MARCH 12, 2024

The antibody-drug conjugate (ADC) Adcetris has given Pfizer’s oncology department its first pivotal trial win from the legacy Seagen portfolio since the $43 billion merger. | The antibody-drug conjugate Adcetris has given Pfizer’s oncology department its first pivotal trial win from the legacy Seagen portfolio since the $43 billion merger.

218

218

Pharmaceutical Commerce

MARCH 12, 2024

A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.

Physicians 111

Physicians Patients 111

Advertisement

Distribution

Fierce Pharma

MARCH 12, 2024

Acacia Pharmaceuticals is calling it quits on future testing of Nuplazid after a string of expansion efforts have come up short. | The company will not conduct any further clinical trials of the drug, which is currently approved to treat Parkinson’s disease psychosis. The decision comes after years of failed expansion bids in other uses.

Pharmaceutical 218

Pharmaceutical 218

Pharmaceutical Commerce

MARCH 12, 2024

A sit-down with Groovy Singh, CEO of Bright Green Corporation, who describes the waves in the global supply chain the company is making after being authorized to grow cannabis, along with cannabis-related products.

Manufacturing 105

Manufacturing 105

MedCity News

MARCH 12, 2024

With pimavanserin’s Phase 3 failure in schizophrenia, Acadia Pharmaceuticals said it will no longer run clinical trials for the drug, whose lone approval is for treating psychosis from Parkinson’s disease. The FDA previously rebuffed regulatory submissions for the drug in dementia and Alzheimer’s disease.

FDA 104

FDA Pharmaceutical Biopharma Pharma 104

PharmaTech

MARCH 12, 2024

In an interview, Fabian Gerlinghaus of Cellares outlines a paradigm change in both hardware and software, regulatory expansions, and some positive cost outcomes for the CGT field.

98

98

MedCity News

MARCH 12, 2024

Four modest system improvements in the U.S. are assisting with valuing and activating people’s families and support networks in health care today.

Networking 101

Networking Patients 101

European Pharmaceutical Review

MARCH 12, 2024

Data integrity is the term used to describe the accuracy, consistency and reliability of data throughout its lifecycle. In the pharmaceutical/life sciences industries, maintaining data integrity is crucial given its role in making critical decisions that shape outcomes from drug development to human health. What are three current key trends in data integrity?

Government 90

Government Pharma Ethics Training 90

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

MARCH 12, 2024

Up to 25,000 patients in England with ulcerative colitis are eligible for treatment with Pfizer’s Velsipity after NICE backed use of the drug on the same day as its MHRA approval.

Patients 85

Patients 85

Pharmaceutical Technology

MARCH 12, 2024

TERN-701 is a BCR-ABL tyrosine-kinase inhibitor being studied in a Phase I study, with data expected in H2 this year.

FDA 105

FDA 105

European Pharmaceutical Review

MARCH 12, 2024

Coating is the oldest and last key unit operation in many tablet production processes. The function of the coating ranges from purely cosmetic improvements (brand recognition, better patient acceptance using API taste masking) to alterations of tablet release characteristics (control of the release profile and bioavailability of the API). Generally, the goal of coating is to generate a thin solid layer around the tablet core.

Distribution 81

Distribution Pharmaceutical Safety Pharma 81

pharmaphorum

MARCH 12, 2024

Healthcare systems need to address the impact of racial and ethnic biases in the design and use of medical devices, says an independent UK review.

Medical 89

Medical Healthcare Healthcare 89

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

PharmaTimes

MARCH 12, 2024

Globally, cancer is currently the most leading cause of death due to disease among children

Leads 100

Leads 100

PharmaVoice

MARCH 12, 2024

As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

Patients 98

Patients 98

pharmaphorum

MARCH 12, 2024

Sanofi says OX40L inhibitor amlitelimab could be a ‘best-in-class’ maintenance therapy for atopic dermatitis after reporting new phase 2b data

79

79

PharmaTimes

MARCH 12, 2024

Between October 2023 and March 2024, the UKHSA said that 733 cases of measles were reported in England

88

88

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

pharmaphorum

MARCH 12, 2024

Acadia Pharma has abandoned plans to develop Nuplazid for additional indications after the drug failed a phase 3 trial in schizophrenia.

Pharma 80

Pharma 80

Pharmaceutical Technology

MARCH 12, 2024

In an exclusive interview, Jaguar Health’s CEO discussed plans for the investigation of crofelemer in human and animal studies.

Pharmaceutical 75

Pharmaceutical 75

pharmaphorum

MARCH 12, 2024

Shares in Regulus Therapeutics leap after the company reports data with its microRNA-targeting drug in polycystic kidney disease, and files a $100m private placement.

57

57

Clarify Health

MARCH 12, 2024

Providing high-quality care while keeping costs under control can often feel mutually exclusive. Health plans want to deliver the best possible care for their members, and that frequently takes a financial investment. But from a business perspective, health plans must find that balance between providing high-quality care at a lower cost for their members, and those that do will reap the benefits of better growth, improved member retention, and enhanced health plan profitability.

Healthcare 52

Healthcare Healthcare Management Leads 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

Evolve Your Success

MARCH 12, 2024

When Brooke Elliott got the chance to mentor medical sales reps to become the industry’s next-generation leaders, she found fulfillment in becoming a full-time coach. In her desire to help even more people, she decided to start BE Complete Coaching & Consulting. In this special episode for Women’s History Month and International Women’s Day, Brooke joins Samuel Adeyinka to share how she brings out the best in medical sales reps today.

Medical sales reps 52

Medical sales reps Medical sales Medical Sales 52

PharmExec

MARCH 12, 2024

Submission is based on positive results from the company’s Phase III QUASAR clinical trial, in which Tremfya (guselkumab) produced positive results treating moderately to severely active ulcerative colitis.

FDA 52

FDA 52

Evolve Your Success

MARCH 12, 2024

In this compelling episode of The Medical Sales Podcats, join Samuel Adeyinka and his special guest, Adam Mostafa , a titan in the field of healthcare sales and Managing Director of Business Development at TruVeta, as he delves into the data revolution transforming the medical device industry. With over a decade of rich experience that stretches from pharmaceuticals to medical devices and now healthcare data analytics, Adam provides unparalleled insights into the power of real-world evidence in

Pharmaceutical Sales 52

Pharmaceutical Sales Healthcare Healthcare Sales 52

PharmaVoice

MARCH 12, 2024

Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.

Competition 52

Competition 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Technology

MARCH 12, 2024

Enhance gene expression and reduce immune responses with Selecta Biosciences' patented method using viral vectors and nanocarriers attached to immunosuppressants. Learn more about this innovative approach for improved therapeutic outcomes.

52

52

PharmExec

MARCH 12, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Media 52

Media 52

Pharmaceutical Technology

MARCH 12, 2024

Johnson & Johnson’s Tremfya is approved for plaque psoriasis and active psoriatic arthritis, with a label for ulcerative colitis now on the horizon.

52

52

PharmExec

MARCH 12, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Medical 52

Medical 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management